Erythrodermic pityriasis rubra pilaris following SARS-CoV-2 vaccination treated with bimekizumab.
作者信息
Saad Mysa, Bose Reetesh
机构信息
Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Division of Dermatology, the Ottawa Hospital, Ottawa, Ontario, Canada.
出版信息
JAAD Case Rep. 2023 Oct 4;42:7-11. doi: 10.1016/j.jdcr.2023.09.024. eCollection 2023 Dec.
Abstract
摘要
相似文献
1
Erythrodermic pityriasis rubra pilaris following SARS-CoV-2 vaccination treated with bimekizumab.
JAAD Case Rep. 2023 Oct 4;42:7-11. doi: 10.1016/j.jdcr.2023.09.024. eCollection 2023 Dec.
2
Erythrodermic pityriasis rubra pilaris after SARS-CoV-2 vaccination with concomitant COVID-19 infection.
J Eur Acad Dermatol Venereol. 2022 Sep;36(9):e675-e676. doi: 10.1111/jdv.18214. Epub 2022 May 16.
3
Comment on: 'Clinical characteristics of patients with pityriasis rubra pilaris following SARS-CoV-2 vaccination' by Gambichler.
J Eur Acad Dermatol Venereol. 2023 Oct;37(10):e1196-e1197. doi: 10.1111/jdv.19264. Epub 2023 Jun 23.
4
Erythrodermic pityriasis rubra pilaris treatment: Two case reports and literature review.
Dermatol Ther. 2020 Nov;33(6):e14223. doi: 10.1111/dth.14223. Epub 2020 Sep 9.
5
Rapid improvement of severe pityriasis rubra pilaris upon treatment with bimekizumab.
Int J Dermatol. 2024 Oct;63(10):1454-1455. doi: 10.1111/ijd.17207. Epub 2024 May 8.
6
[Acute pityriasis rubra pilaris in the child. Apropos of 4 cases].
Ann Dermatol Venereol. 1983;110(3):221-8.
7
Pityriasis rubra pilaris: a review of diagnosis and treatment.
J Am Acad Dermatol. 1989 May;20(5 Pt 1):801-7. doi: 10.1016/s0190-9622(89)70093-1.
8
Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis.
Br J Dermatol. 2022 Nov;187(5):650-658. doi: 10.1111/bjd.21708. Epub 2022 Jul 15.
9
Dermatomyositis with a pityriasis rubra pilaris-like eruption: an uncommon cutaneous manifestation in dermatomyositis.
Pediatr Dermatol. 2007 Mar-Apr;24(2):151-4. doi: 10.1111/j.1525-1470.2007.00364.x.
10
Surgical Management of Cicatricial Ectropion in Pityriasis Rubra Pilaris.
Ophthalmic Plast Reconstr Surg. 2016 Jan-Feb;32(1):e12-5. doi: 10.1097/IOP.0000000000000385.
引用本文的文献
1
Efficacy of Bimekizumab in the Management of Refractory Erythrodermic Pityriasis Rubra Pilaris: Clinical Insights.
Dermatol Pract Concept. 2025 Jul 31;15(3):5316. doi: 10.5826/dpc.1503a5316.
2
Erythroderma Following Pfizer-BioNTech COVID-19 Vaccination in a Patient With Atopic Dermatitis: A Case Report.
Cureus. 2024 Sep 8;16(9):e68936. doi: 10.7759/cureus.68936. eCollection 2024 Sep.
3
Emerging Role of Biologic Drugs Targeting IL-17 and IL-23: Pityriasis Rubra Pilaris.
Life (Basel). 2024 Jul 24;14(8):923. doi: 10.3390/life14080923.
本文引用的文献
1
Pityriasis rubra pilaris following COVID-19 vaccination successfully treated with ixekizumab.
JAAD Case Rep. 2023 May;35:52-56. doi: 10.1016/j.jdcr.2023.03.003. Epub 2023 Mar 15.
2
Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis.
Br J Dermatol. 2022 Nov;187(5):650-658. doi: 10.1111/bjd.21708. Epub 2022 Jul 15.
3
Erythrodermic pityriasis rubra pilaris after SARS-CoV-2 vaccination with concomitant COVID-19 infection.
J Eur Acad Dermatol Venereol. 2022 Sep;36(9):e675-e676. doi: 10.1111/jdv.18214. Epub 2022 May 16.
4
Pityriasis rubra pilaris potentially triggered by messenger RNA-1273 COVID vaccine.
JAAD Case Rep. 2022 May;23:114-116. doi: 10.1016/j.jdcr.2022.03.013. Epub 2022 Apr 1.
5
Pityriasis rubra pilaris in association with inactivated SARS-CoV-2 vaccine (CoronaVac).
Dermatol Ther. 2022 Jun;35(6):e15455. doi: 10.1111/dth.15455. Epub 2022 Mar 28.
6
[Pityriasis rubra pilaris after COVID-19 vaccination: causal relationship or coincidence?].
Dermatologie (Heidelb). 2022 Aug;73(8):634-637. doi: 10.1007/s00105-022-04972-z. Epub 2022 Mar 16.
7
Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: unravelling a possible common trigger, the COVID-19 vaccine.
Clin Exp Dermatol. 2022 Feb;47(2):437-440. doi: 10.1111/ced.14970. Epub 2021 Oct 21.
8
An old entity, a new trigger: Post COVID-19 vaccine pityriasis rubra pilaris.
Int J Risk Saf Med. 2021;32(4):261-264. doi: 10.3233/JRS-210048.
9
Evaluation of Ixekizumab Treatment for Patients With Pityriasis Rubra Pilaris: A Single-Arm Trial.
JAMA Dermatol. 2020 Jun 1;156(6):668-675. doi: 10.1001/jamadermatol.2020.0932.
10
Interleukin 23-Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris.
JAMA Dermatol. 2017 Apr 1;153(4):304-308. doi: 10.1001/jamadermatol.2016.5384.
Zotero 插件